A multicenter cohort study of primary hypertension in Korea: study design and interim analysis of the Korean registry of target organ damage in hypertension (KorHR)

Suk-Won Choi, Seong Woo Han, Jong Sun Ok, Byung-Su Yoo, Mi-Seung Shin, Sung Ha Park, Kyu-Hyung Ryu, Suk-Won Choi, Seong Woo Han, Jong Sun Ok, Byung-Su Yoo, Mi-Seung Shin, Sung Ha Park, Kyu-Hyung Ryu

Abstract

Background: The Korean Registry of Target Organ Damage in Hypertension aims to evaluate the clinical characteristics and prevalence of subclinical target organ damage in Korean hypertensive patients.

Method: This is a prospective, observational, multicenter cohort study in which 23 university hospitals participated. Since May 2013, we have enrolled 1,318 consecutive hypertensive patients without known cardiovascular disease who met the following inclusion criteria: 1) age older than 30 years and 2) the first visit to the participating hospitals was within the last 5 years.

Results: The mean age was 52 ± 12 years; 62.1% were male, and 41.3% were incident hypertensives. Patients with diabetes mellitus accounted for 7.8% of the population and 43.8% had hyperlipidemia or were on statins at baseline. The mean office blood pressures were 152 ± 20/96 ± 14 mmHg for incident hypertensive patients and 129 ± 13/78 ± 10 mmHg for patients on treatment. Patients with electrocardiographic and echocardiographic left ventricular hypertrophy accounted for 18.9 and 25.6%, respectively. The mean brachial-ankle pulse wave velocity (PWV) was 1564 ± 293 m/s and 19.5% had PWV values of more than 1750 cm/s. Patients with microalbuminuria and chronic kidney disease accounted for 21 and 4%, respectively. The first prescribed class of antihypertensive medications was angiotensin converting enzyme inhibitors in 2.9%, angiotensin receptor blockers (ARBs) in 57.5%, diuretics in 7.6%, calcium channel blockers (CCBs) in 61.0%, beta blockers in 17.3%, and fixed dose combination pill in 27.8%.

Conclusion: Our interim analysis shows that subclinical target organ damage in hypertension is considerably present for incident or treated hypertensive patients. CCBs and ARBs were the most commonly prescribed classes of antihypertensive medications and fixed dose combination pills were actively used in Korea.

Trial registration: NCT01861080. Registered 16 May 2013.

Keywords: Hypertension; Target organ damage.

Figures

Fig. 1
Fig. 1
Values of Twenty-four hour ambulatory blood pressure monitoring. 24 h, 24 h average; SBP, systolic blood pressure; DBP, diastolic blood pressure; Day, awake time average; Night, sleep time average
Fig. 2
Fig. 2
Prevalence of subclinical target organ damage. SOD, subclinical organ damage; Echo LVH, echocardiographic left ventricular hypertrophy; ECG LVH, electrocardiographic left ventricular hypertrophy; MAU, microalbuminuria; CKD, chronic kidney disease; PWV, pulse wave velocity

References

    1. Whelton PK. Epidemiology of hypertension. Lancet. 1994;344:101–106. doi: 10.1016/S0140-6736(94)91285-8.
    1. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4–16. doi: 10.1097/HJH.0b013e32834000be.
    1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC) Eur Heart J. 2013;34:2159–2219. doi: 10.1093/eurheartj/eht151.
    1. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American heart association council on high blood pressure research. Hypertension. 2005;45:142–161. doi: 10.1161/01.HYP.0000150859.47929.8e.
    1. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European society of cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–1463. doi: 10.1016/j.echo.2005.10.005.
    1. Redon J. Urinary albumin excretion: lowering the threshold of risk in hypertension. Hypertension. 2005;46:19–20. doi: 10.1161/01.HYP.0000169154.94803.35.
    1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
    1. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254. doi: 10.7326/0003-4819-145-4-200608150-00004.
    1. Kawai T, Ohishi M, Onishi M, Ito N, Takeya Y, Maekawa Y, et al. Cut-off value of brachial-ankle pulse wave velocity to predict cardiovascular disease in hypertensive patients: a cohort study. J Atheroscler Thromb. 2013;20:391–400. doi: 10.5551/jat.15040.
    1. Munakata M, Konno S, Miura Y, Yoshinaga K. Prognostic significance of the brachial-ankle pulse wave velocity in patients with essential hypertension: final results of the J-TOPP study. Hypertens Res. 2012;35:839–842. doi: 10.1038/hr.2012.53.
    1. Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002;39:744–749. doi: 10.1161/hy0302.104669.
    1. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26:343–349. doi: 10.1038/jhh.2011.104.
    1. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2004;43:731–738. doi: 10.1161/.
    1. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the cardiovascular health study. J Am Coll Cardiol. 2004;43:2207–2215. doi: 10.1016/j.jacc.2003.11.064.
    1. Leoncini G, Sacchi G, Ravera M, Viazzi F, Ratto E, Vettoretti S, et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens. 2002;16:399–404. doi: 10.1038/sj.jhh.1001408.
    1. Halimi JM, Forhan A, Balkau B, Novak M, Wilpart E, Tichet J, et al. Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk. 2001;8:139–146. doi: 10.1097/00043798-200106000-00004.
    1. de la Sierra A, Bragulat E, Sierra C, Gomez-Angelats E, Antonio MT, Aguilera MT, et al. Microalbuminuria in essential hypertension: clinical and biochemical profile. Br J Biomed Sci. 2000;57:287–291.
    1. Calvino J, Calvo C, Romero R, Gude F, Sanchez-Guisande D. Atherosclerosis profile and microalbuminuria in essential hypertension. Am J Kidney Dis. 1999;34:996–1001. doi: 10.1016/S0272-6386(99)70003-X.
    1. Leoncini G, Viazzi F, Rosei EA, Ambrosioni E, Costa FV, Leonetti G, et al. Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. J Hypertens. 2010;28:156–162. doi: 10.1097/HJH.0b013e328332038c.
    1. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens. 1997;11:727–732. doi: 10.1038/sj.jhh.1000459.
    1. Cerasola G, Cottone S, Mule G, Nardi E, Mangano MT, Andronico G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens. 1996;14:915–920. doi: 10.1097/00004872-199607000-00016.
    1. Choi HS, Sung KC, Lee KB. The prevalence and risk factors of microalbuminuria in normoglycemic, normotensive adults. Clin Nephrol. 2006;65:256–261. doi: 10.5414/CNP65256.
    1. Kim YS, Kim HS, Oh HY, Lee MK, Kim CH, Kim YS, et al. Prevalence of microalbuminuria and associated risk factors among adult Korean hypertensive patients in a primary care setting. Hypertens Res. 2013;36:807–823. doi: 10.1038/hr.2013.44.
    1. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002;39:445–459. doi: 10.1053/ajkd.2002.31388.
    1. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the gubbio population study. Arch Intern Med. 1998;158:1933–1939. doi: 10.1001/archinte.158.17.1933.
    1. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC study. Microalbuminuria: a Genoa investigation on complications. Hypertension. 1997;30:1135–1143. doi: 10.1161/01.HYP.30.5.1135.
    1. Palatini P, Graniero GR, Mormino P, Mattarei M, Sanzuol F, Cignacco GB, et al. Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the hypertension and ambulatory recording Venetia study (HARVEST study) Am J Hypertens. 1996;9:334–341. doi: 10.1016/0895-7061(95)00391-6.
    1. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–2605. doi: 10.1093/eurheartj/ehl254.
    1. Ninomiya T, Kojima I, Doi Y, Fukuhara M, Hirakawa Y, Hata J, et al. Brachial-ankle pulse wave velocity predicts the development of cardiovascular disease in a general Japanese population: the hisayama study. J Hypertens. 2013;31:477–483. doi: 10.1097/HJH.0b013e32835c5c23.
    1. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens. 2009;27:2022–2027. doi: 10.1097/HJH.0b013e32832e94e7.
    1. Hae Guen S, Eung Ju K, Hong Seog S, Seong Hwan K, Chang Gyu P, Seong Woo H, et al. Relative contributions of different cardiovascular risk factors to significant arterial stiffness. Int J Cardiol. 2010;139:263–268. doi: 10.1016/j.ijcard.2008.10.032.
    1. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens. 2012;30:1928–1936. doi: 10.1097/HJH.0b013e328356c579.
    1. Watson RE, Karnchanasorn R, Gossain VV. Hypertension in Asian/Pacific Island Americans. J Clin Hypertens (Greenwich) 2009;11:148–152. doi: 10.1111/j.1751-7176.2009.00088.x.
    1. Stanton T, Reid JL. Fixed dose combination therapy in the treatment of hypertension. J Hum Hypertens. 2002;16:75–78. doi: 10.1038/sj.jhh.1001312.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다